跳至主要内容
临床试验/EUCTR2008-007546-56-DE
EUCTR2008-007546-56-DE进行中(未招募)不适用

A Phase II Multicentre Study of perioperative Chemotherapy for resectable Adenocarcinoma of the Gastroesophageal Junction and of the Stomach

Klinikum der Universität München, Campus Großhadern0 个研究点开始时间: 2009年8月21日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • By means of push-endoscopy (PE) histologically confirmed adenocarcinoma of the gastroesophageal junction (GEJ I-III) and the stomach (every T, N + T3/T4, Nx, M0)
  • Signed written consent of the patient
  • Age = 18
  • Expectedness that surgery may be performed
  • ECOG-Performance-Status = 2
  • Laparoscopic exclusion of peritoneal carcinoma
  • Adequate haematological, renal, cardiac and hepatic function: leukocytes = 3.0 * 109/l; neutrophiles = 1.5 * 109/l; thrombocytes = 100* 109/l; haemoglobin = 9.7 g/dl; serum creatinine 1.25 * upper limit of the normal range (ULNR) or creatinine clearance > 60 ml/min; serum bilirubin = 1.25 * ULNR; ALAT and ASAT = 1. 5 * ULNR
  • Effective contraceptive measures for men and women
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Pre-existing chemotherapy or radiotherapy for the gastroesophagal junction or the adenocarcinoma
  • Non-histologically confirmed primary tumor
  • Distant metastasis
  • Known hypersensitivity against 5-Flourouracil, Leucovorin, Oxaliplatin or Docetaxel
  • Known dihydropyrimdine dehydrogenase (DPD) deficiency
  • Peripheral polyneuropathy = grade II (NCI-CTCAE, version 3.0)
  • Myocardial infarction in the last 3 months, heart insufficiency grade II-IV (NYHA)
  • Severe concomitant diseases or acute infections
  • Known drug usage or medication abuse
  • Pregnant or lactant women
  • Insufficient contraception
  • A simultaneous or within a time period of 30 days, participation in studies with one or multiple number of drugs under investigation
  • Second neoplasia = 5 years prior study entry (exception: carcinoma in situ of the cervix uteri and an adequately treated basal cell carcinoma)
  • Missing or limited contractual capability

研究者

发起方
Klinikum der Universität München, Campus Großhadern

相似试验